Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
CytoMed Therapeutics (NASDAQ: GDTC) has successfully completed dose level 1 of its ANGELICA Trial, a Phase I dose-escalation clinical study evaluating CTM-N2D in late-stage cancer patients. The company plans to proceed with dose level 2 in Q3 2025.
The trial focuses on CTM-N2D, an innovative allogeneic NKG2DL-targeting CAR gamma delta T cell therapy designed to treat advanced solid tumors and blood cancers. Unlike traditional CAR-T therapies, CTM-N2D uses donor-derived cells that don't require patient matching, potentially offering a more accessible treatment option. The therapy targets NKG2DL, proteins commonly found in various cancers, providing a potentially broader application compared to conventional treatments.
CytoMed Therapeutics (NASDAQ: GDTC) ha completato con successo il livello di dose 1 del suo studio ANGELICA, uno studio clinico di Fase I a dose crescente che valuta CTM-N2D in pazienti con tumori in fase avanzata. L'azienda prevede di procedere con il livello di dose 2 nel terzo trimestre 2025.
Lo studio si concentra su CTM-N2D, una innovativa terapia con cellule T gamma delta CAR allogeniche che mirano a NKG2DL, progettata per trattare tumori solidi avanzati e tumori del sangue. A differenza delle tradizionali terapie CAR-T, CTM-N2D utilizza cellule derivate da donatori che non richiedono compatibilità con il paziente, offrendo potenzialmente un'opzione terapeutica più accessibile. La terapia prende di mira NKG2DL, proteine comunemente presenti in diversi tipi di cancro, offrendo un'applicazione potenzialmente più ampia rispetto ai trattamenti convenzionali.
CytoMed Therapeutics (NASDAQ: GDTC) ha completado con éxito el nivel de dosis 1 de su ensayo ANGELICA, un estudio clínico de Fase I con escalada de dosis que evalúa CTM-N2D en pacientes con cáncer en etapa avanzada. La compañía planea avanzar con el nivel de dosis 2 en el tercer trimestre de 2025.
El ensayo se centra en CTM-N2D, una innovadora terapia con células T gamma delta CAR alogénicas que apuntan a NKG2DL, diseñada para tratar tumores sólidos avanzados y cánceres hematológicos. A diferencia de las terapias CAR-T tradicionales, CTM-N2D utiliza células derivadas de donantes que no requieren compatibilidad con el paciente, lo que podría ofrecer una opción de tratamiento más accesible. La terapia se dirige a NKG2DL, proteínas comúnmente encontradas en varios tipos de cáncer, proporcionando una aplicación potencialmente más amplia en comparación con los tratamientos convencionales.
CytoMed Therapeutics (NASDAQ: GDTC)가 후기 � 환자� 대상으� CTM-N2D� 평가하는 1� 용량 증량 임상 시험� ANGELICA 시험� 1단계 용량� 성공적으� 완료했습니다. 회사� 2025� 3분기� 2단계 용량으로 진행� 계획입니�.
� 시험은 진행� 고형� � 혈액� 치료� 위해 설계� 혁신적인 동종 NKG2DL 표적 CAR 감마 델타 T 세포 치료�� CTM-N2D� 중점� 둡니�. 기존� CAR-T 치료제와 달리 CTM-N2D� 환자 맞춤� 필요 없는 기증� 유래 세포� 사용하여 보다 접근하기 쉬운 치료 옵션� 제공� 가능성� 있습니다. � 치료법은 다양� 암에� 흔히 발견되는 NKG2DL 단백질을 표적으로 하여 기존 치료법보� � 폭넓은 적용� 기대됩니�.
CytoMed Therapeutics (NASDAQ : GDTC) a réussi à compléter le niveau de dose 1 de son essai ANGELICA, une étude clinique de phase I avec escalade de dose évaluant CTM-N2D chez des patients atteints de cancers avancés. La société prévoit de passer au niveau de dose 2 au troisième trimestre 2025.
L’essai porte sur CTM-N2D, une thérapie innovante par cellules T gamma delta CAR allogéniques ciblant NKG2DL, conçue pour traiter les tumeurs solides avancées et les cancers du sang. Contrairement aux thérapies CAR-T traditionnelles, CTM-N2D utilise des cellules dérivées de donneurs qui ne nécessitent pas d’appariement avec le patient, offrant potentiellement une option de traitement plus accessible. La thérapie cible NKG2DL, des protéines couramment présentes dans divers cancers, offrant une application potentiellement plus large comparée aux traitements conventionnels.
CytoMed Therapeutics (NASDAQ: GDTC) hat erfolgreich die Dosisstufe 1 seiner ANGELICA-Studie abgeschlossen, einer Phase-I-Dosissteigerungsstudie zur Bewertung von CTM-N2D bei Patienten mit fortgeschrittenem Krebs. Das Unternehmen plant, im dritten Quartal 2025 mit Dosisstufe 2 fortzufahren.
Die Studie konzentriert sich auf CTM-N2D, eine innovative allogene CAR-Gamma-Delta-T-Zelltherapie, die auf NKG2DL abzielt und zur Behandlung fortgeschrittener solider Tumoren und Blutkrebserkrankungen entwickelt wurde. Im Gegensatz zu herkömmlichen CAR-T-Therapien verwendet CTM-N2D donorabgeleitete Zellen, die keine Patientenanpassung erfordern, was potenziell eine zugänglichere Behandlungsoption bietet. Die Therapie zielt auf NKG2DL ab, Proteine, die häufig in verschiedenen Krebsarten vorkommen, und bietet somit eine potenziell breitere Anwendung im Vergleich zu herkömmlichen Behandlungen.
- Successful completion of dose level 1 in Phase I trial
- Therapy doesn't require donor-patient compatibility matching, improving accessibility
- Technology targets multiple cancer types (solid tumors and blood cancers)
- More selective targeting compared to chemotherapy, potentially reducing side effects
- Still in early clinical development (Phase I)
- Efficacy data not yet reported
- Results limited to only four patients in dose level 1
Insights
CytoMed's ANGELICA trial advances to dose level 2 after successful safety completion of level 1, showing progress for their allogeneic CAR gamma delta T cell therapy.
CytoMed Therapeutics has reached a significant clinical milestone with their ANGELICA Trial, successfully completing dose level 1 in four late-stage cancer patients and preparing to advance to dose level 2 in Q3 2025. This Phase I dose-escalation study is evaluating CTM-N2D, their allogeneic NKG2DL-targeting CAR gamma delta T cell therapy for advanced solid tumors and blood cancers.
The technical innovation here deserves attention. CTM-N2D leverages gamma delta T cells from healthy donors rather than the patient's own cells, potentially offering substantial manufacturing and logistics advantages. Unlike conventional CAR-T therapies that require harvesting a patient's own T cells, CTM-N2D doesn't require donor-patient matching, which could significantly broaden patient accessibility and reduce production complexities.
While completion of dose level 1 suggests acceptable initial safety, it's important to recognize this is just the first step in the safety evaluation process. The trial appears to be following a standard dose-escalation design to identify the maximum tolerated dose while monitoring for adverse events. No efficacy data has been released at this stage, which is typical for early dose-escalation phases.
The targeting mechanism—focusing on NKG2D ligands that are commonly overexpressed across multiple cancer types—represents a potentially versatile approach. This basket trial design investigating both solid and hematological malignancies indicates the company is exploring broad applications rather than focusing on a single cancer type initially.
This milestone keeps CytoMed on their clinical timeline, but investors should understand that dose level 1 completion primarily demonstrates preliminary safety rather than efficacy, with substantive clinical outcomes still to be determined in later trial phases.
SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our , CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed� or “Company�), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce the successful completion of dose level 1 for its first-in-human Phase I dose-escalation clinical trial () (“ANGELICA Trial�) for four late stage cancer patients and is scheduled to start dose level 2 of the ANGELICA Trial in third quarter of 2025.
The ANGELICA Trial evaluates the safety and tolerability of allogeneic NKG2DL-targeting chimeric antigen receptor-grafted (CAR) gamma delta T cells (CTM-N2D) in the treatment of a basket of cancer indications that include advanced solid and haematological malignancies. Refer to our announcement on for more information regarding the ANGELICA Trial.
CTM-N2D uses a subtype of T cells known as gamma delta T cells which are derived from healthy donors, which are expanded and modified to express CAR that targets NKG2DL that are commonly present in many cancers. CTM-N2D can be infused into patients without the need for donor-patient compatibility matching.
This differs from conventional CAR-αβ T cell therapies that typically involve the collection of patient’s own blood cells and modifying these cells to express cancer-targeting CARs. The modified αβ T cells are then re-infused back into the patient to target and kill cancer cells. Unlike chemotherapy that targets all actively dividing cells including healthy ones, CAR-T cells specifically recognize targets (antigen) present on cancer cells to kill them.
About CytoMed Therapeutics Limited (CytoMed)
Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. For more information, please visit and follow us on Twitter (“X�) ,on , and .
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,� “should,� “believe,� “expect,� “anticipate,� “project,� “estimate� or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company’s current and future pre-clinical studies and clinical trials and the Company’s R&D programs; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company’s ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.
Contact:
CytoMed Therapeutics Limited
[email protected]
Attention : Evelyn Tan, Chief Corporate Officer
